After almost 20 years of running separate funds, Stuart Weisbrod and Jacob Gottlieb are now back under one roof. The two healthcare investing titans know each other very well through their earlier work together at a company called Merlin BioMed Group, and they’re now sharing offices with a coming collaboration in the works.
In 1998, Stuart Weisbrod co-founded Merlin as an investment managing firm that was focusing on the sector of healthcare with portfolios in the healthcare service, medical device, pharmaceutical, and biotechnology sectors. He has had a thriving track record in biotechnology and healthcare investment, which includes positions with Prudential-Bache Securities, Merrill Lynch, Harpel Partners, and Oracle Partners.
Weisbrod has a Bachelor of Arts in Chemistry, which he received in 1975 from Colgate University; a Master of Business Administration degree, which he received in 1986 from Columbia University; and a Doctor of Philosophy in Biochemistry, which he earned in 1980 from Princeton University. His professional background gave him the network and the necessary expertise to form a winning team.
The team included Gottlieb, who was working for Weisbrod in 2000 as a portfolio manager. While Gottlieb was working at Merlin at the rise of the biotechnology revolution, he helped Merlin to achieve returns of more than 100% in 1999 and 2000. Jacob Gottlieb together with other portfolio managers was successful to generate large returns; this helped them to get prominent clients including high net worth individuals, family offices, endowments, and major pension funds. Despite many years of success, Merlin BioMed Group returned all the funds to investors and in 2007, it closed its doors.
Since winding up Merlin, Stuart Weisbrod went on and created another investment company known as Iguana Healthcare Partners. Generally, the investment strategy that’s behind Iguana Healthcare Partners is similar to Merlin BioMed Group. Gottlieb also went on and created his own company after leaving Merlin BioMed Group; he founded a company called Visium Asset Management with 300 million dollars in starting capital. The firm rapidly grew to $8 billion.
In 2016, Visium Asset Management’s business came to an end when 3 executives were accused of mismarking and insider trading. Now that Gottlieb and Weisbrod are working from one office, the industry will definitely witness some impressive changes and great, new thing for opportunities in the healthcare investment.